Source: The Business Journals

PellePharm: With 'breakthrough' skin cancer drug, small S.F. drug maker lands European cash

On the cusp of taking its drug into a late-stage clinical trial for a rare genetic skin condition, a small San Francisco drug developer scored a potential $760 million deal with Danish drug maker Leo Pharma A/S. The pact, including an initial $70 million in equity and research-and-development support, gives PellePharm Inc. enough money to complete the Phase III study in people with Gorlin Syndrome. That skin condition today, while not a health threat, can lead to as many as 30 procedures a year...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Sanuj K. Ravindran's photo - President & CEO of PellePharm

President & CEO

Sanuj K. Ravindran

CEO Approval Rating

82/100

Read more